Before anything else
The math: Rezdiffra, Madrigal’s liver-disease drug, went from essentially zero revenue to nearly a billion dollars in a single year, and the most recent quarter showed sales still growing at 71% year over year. The mood, meaning what the market is currently paying, prices the stock well below the company’s own historical median valuation. A business growing this fast, trading at a multiple this compressed, raises a question the filings alone cannot answer: what assumptions separate the two readings, and which variables would have to shift to close the gap? The gap is what the filings help quantify.
From zero to a billion, in one lap
For most of its life, Madrigal was a research organization with a promising molecule and no revenue. The 10-K for fiscal year 2023 shows exactly $0 in product sales. Then the FDA approved Rezdiffra in March 2024 as the first-ever treatment for MASH, a liver-scarring disease driven by fat accumulation that affects tens of millions of Americans. The 10-K for fiscal year 2025 records $958 million in revenue. That is not a rounding error. That is a company that did not exist commercially two years ago, now closing in on a billion-dollar run rate.
The tension is that the company is still losing money, and losing it at scale. A net margin deep in negative territory in fiscal 2025 means that for every dollar Rezdiffra brought in, Madrigal spent more than a dollar. That sounds alarming until you understand why: launching a new drug costs an enormous amount up front, in sales forces, medical education, and manufacturing, before the revenue catches up. The question is whether the revenue is catching up fast enough.
What the August 8-K filed, and what it skipped
The most recent SEC filing closest to today is an 8-K filed August 12, 2026, announcing the appointment of John C. Reed, M.D., Ph.D., to the board of directors. Reed is a cancer biologist with deep drug-development experience, expanding the board by one seat. That is a governance footnote, not a financial event. The real news was already in the 10-Q for the quarter ended June 30, 2026, filed July 30.
The 10-Q for the quarter ended June 30, 2026 shows Rezdiffra net sales of $364 million in Q2 2026 alone, up 71% from the same quarter a year earlier. More than 49,000 patients were on therapy as of June 30. To feel what that means: a year ago, the drug was new and doctors were cautious; today it is treating a city the size of Santa Clara, and the count is still climbing. The net loss for the quarter was meaningful but shrinking relative to revenue, and the company held enough cash to represent several years of cushion at the current burn rate, without requiring near-term fundraising.
The pipeline is no longer a single bet
What changed most between filings is not the Rezdiffra numbers. It is the pipeline behind them. In January 2026, Madrigal licensed ervogastat from Pfizer, an oral compound that blocks the enzyme responsible for assembling fat in liver cells, with a Phase 2 combination trial planned for 2027. In May 2026, the company added MGL-0795, a gene-silencing drug licensed from Arrowhead Pharmaceuticals that targets a genetic variant found in a large share of MASH patients. And in Q2 2026, Madrigal dosed the first patient in a Phase 1 trial for MGL-2086, its own oral GLP-1 candidate, the same class of mechanism behind the weight-loss drugs that have reshaped metabolic medicine.
A single approved drug is a product. Three clinical-stage assets behind it, plus six earlier-stage gene-silencing programs acquired from Suzhou Ribo Life Science, starts to look like a platform. Whether that platform justifies a higher price is what the market is currently arguing with itself about.
The patent wall, and what it protects
One detail that rarely makes headlines but matters enormously: three new U.S. resmetirom patents were issued in June 2026, extending protection on treatment regimens and cirrhosis patients well into the 2040s. That represents nearly two decades of runway on the core product, a variable that analysts typically weigh when modeling how long a revenue trajectory has to compound before generic competition enters.
Reading the numbers
- $364 million, Q2 2026 Rezdiffra net sales (10-Q, June 30, 2026): what it is, the drug’s quarterly revenue. What it means here: annualized, that pace exceeds $1.4 billion, well above the $958 million full-year 2025 figure. In everyday terms: a business that billed roughly $80 million a month in its first full commercial year is now billing roughly $120 million a month.
- 49,000+ patients on therapy, June 30, 2026: what it is, the real-world patient count. What it means here: MASH is estimated to affect millions of Americans with moderate to advanced fibrosis, so 49,000 is early penetration, not saturation. In everyday terms: if the eligible pool were a stadium of 100,000 people, fewer than half the seats are filled.
- $839 million cash, June 30, 2026: what it is, the company’s liquid reserves. What it means here: at a quarterly net loss of $58 million, this represents roughly three and a half years of losses at the current rate, before revenue growth narrows that gap further. In everyday terms: a household spending $1,000 a month more than it earns, but holding $42,000 in savings, has time to fix the gap before a crisis.
- Price-to-sales of 13, vs. historical median of 39.8 (BullScope valuation dataset, methodology at bullscope.ai/methodology, covering fiscal years 2019–2025): what it is, the price tag per dollar of annual revenue. What it means here: the current multiple sits well below the historical median. That gap could reflect market skepticism about whether growth continues, a structural re-rating now that Rezdiffra is a commercial product rather than a pipeline asset, or some combination of both, each of which would imply a different analytical conclusion. IF the multiple were to revert toward the historical median AND revenue held near its current annualized pace, the arithmetic would point to a materially different price; IF the market’s skepticism about growth durability proves correct, the current multiple may be appropriate or even elevated. Neither outcome is implied by the data alone. In everyday terms: a coffee shop that used to sell for 40 times its annual revenue is now priced at 13 times. Whether that reflects a changed business model, changed market conditions, or a mispricing is the question the multiple alone cannot resolve.
Sources
- 10-Q for quarter ended June 30, 2026, SEC EDGAR
- 10-K for fiscal year ended December 31, 2025, SEC EDGAR
- 10-K for fiscal year ended December 31, 2024, SEC EDGAR
- 10-K for fiscal year ended December 31, 2023, SEC EDGAR
- 8-K filed August 12, 2026, StockTitan
- FDA approval announcement, March 2024
- Madrigal ervogastat license announcement, January 2026, GlobeNewswire
- Madrigal new resmetirom patents announcement, July 2026, StockTitan
